203
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Temocillin: Is this the Right Momentum for its Global Use?

, &
Pages 81-83 | Received 15 Nov 2018, Accepted 03 Dec 2018, Published online: 15 Jan 2019
 

Financial & competing interests disclosure

The authors have received antimicrobial susceptibility reagents from Eumedica SA Dr Balakrishnan has received lecture fees, support for research and sponsorship for conferences from Eumedica SA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

The authors have received antimicrobial susceptibility reagents from Eumedica SA Dr Balakrishnan has received lecture fees, support for research and sponsorship for conferences from Eumedica SA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.